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Vitiligo is a cutaneous pigmentary disorder charac-
terized by the loss of melanocytes. An autoimmune
mechanism is strongly suspected to be involved in
this affection given that it is frequently associated
with autoimmune hormonal disorders, and because
antibodies directed against melanocytic antigens are
found in the serum of patients with vitiligo.
We examined the role of cellular immunity in
melanoma-associated vitiligo by expanding in®ltrat-
ing lymphocytes from fresh biopsy specimens of
vitiligo patches in melanoma patients. The vitiligo-
in®ltrating lymphocytes were almost exclusively
T lymphocytes, and most were CD8+. Following
in vitro expansion, vitiligo-in®ltrating lymphocytes
remained predominantly CD8+ and expressed the
cutaneous homing receptor CLA. Furthermore,
vitiligo-in®ltrating lymphocytes had a clonal or
oligoclonal T cell receptor pro®le, possibly re¯ecting
speci®c antigenic stimulation. Finally, vitiligo-
in®ltrating lymphocytes speci®cally recognized
differentiation antigens shared by normal melano-
cytes and melanoma cells. This direct demonstration
of CD8+ T cell involvement in vitiligo suggests that,
in melanoma patients, vitiligo may be a visible effect
of a spontaneous antitumoral immune response. Key
words: melanoma/skin/T lymphocytes/tumor immunity/
vitiligo. J Invest Dermatol 117:1464±1470, 2001
V
itiligo is a skin disorder characterized by patchy
depigmented macules resulting from a loss of
melanocytes. Pathophysiologic hypotheses to explain
this pathology include autocytotoxic, neural, and
immunologic mechanisms. The association of vitiligo
with autoimmune diseases, as well as the presence of antibodies
directed against melanocyte antigens involved in melanin synthesis
(Naughton et al, 1983; Cui et al, 1992; Song et al, 1994), favor an
immunologic mechanism. Moreover, the recent observation of the
adoptive transfer of vitiligo following allogeneic bone marrow
transplantation for non-Hodgkin's lymphoma represents a new
argument for an immunologic origin of vitiligo (Neumeister et al,
2000). The statistically signi®cant association between vitiligo and
melanoma is generally considered as a sign of good prognosis. This
observation suggests that vitiligo might result from an antitumoral
response directed against differentiation antigens shared by normal
melanocytes and melanoma cells. The particularly high frequency
of vitiligo in melanoma patients treated with recombinant
cytokines (Le Gal et al, 1996; Rosenberg and White, 1996) further
supports this hypothesis, and is indicative of the involvement of
cellular immune effectors. Although recent studies have highlighted
intralesional lymphocytic in®ltrates (Badri et al, 1993; Le Poole et al,
1996) and melanocyte-antigen-speci®c circulating CD8+ T cells in
nonmelanoma vitiligo patients (Ogg et al, 1998), the functional role
of vitiligo-in®ltrating T lymphocytes (VIL) in melanocyte destruc-
tion has not yet been directly demonstrated.
We therefore determined the phenotype and antigenic speci®-
city of VIL expanded from depigmented skin samples of patients
with melanoma.
MATERIALS AND METHODS
Patients and samples We prospectively included in this study ®ve
patients with histologically documented melanoma, who developed
vitiligo at various time points in the course of the malignancy. Following
the approval of this research project by the local ethics committee,
written informed consent was obtained from each patient.
Patient 1 (HLA-A2/-A68, -B18/-B35), a 32-y-old male, presented
with a metastatic melanoma. He developed vitiligo at the end of
fotemustine therapy, which led to the complete regression of all
identi®ed metastases.
Patient 2 (HLA-A3/-A24, -B7/-B18), a 63-y-old male, presented
with a vitiligo that developed 2 y after surgical resection of a primary
melanoma in 1985. The malignancy has not relapsed.
In patient 3 (HLA-A3/-A29, -B7/-B44), a 62-y-old male, the
diagnosis of melanoma was based on lymph node metastases from an
unidenti®ed primary tumor. Vitiligo occurred about a year prior to the
diagnosis, possibly coinciding with regression of the primary tumor. The
depigmentation increased during interferon-a (IFN-a) therapy.
Patient 4 (HLA-A2/-A29, -B44/-), a 55-y-old male, presented a
metastatic melanoma. Vitiligo developed after 1 y of cisplatin/interleu-
kin-2 (IL-2) therapy, which resulted in stabilization of the metastatic
disease.
In patient 5 (HLA-A1/-A26, -B44/-), a 73-y-old male, the diagnosis
of melanoma was based on a colon metastase from an unidenti®ed
primary tumor. Vitiligo developed about 5 y prior to the diagnosis and
spread until 6 mo before this study.
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Skin biopsy specimens were taken from the inner border of vitiligo
patches for histologic analysis and expansion of VIL. Likewise, 20 ml of
blood were withdrawn from each patient and anticoagulated with lithium
heparinate.
Control biopsies from other skin conditions were taken from a 21-y-
old male patient (HLA-A1/-A33, -B14/-) with diffuse lichen planus and
a 25-y-old male patient (HLA-A3/-B27/-) with a recent eruption of
secondary syphilis.
HLA class I phenotyping HLA class I phenotyping was performed on
fresh peripheral blood mononuclear cells (PBMC) using serologic
methods (One Lambda, Canoga Park, CA).
Peptides Thirteen melanoma-associated antigenic epitopes known to
be presented by the patients' HLA class I molecules were synthesized and
characterized by Neosystem (Strasbourg, France): tyrosinase 1±9 (HLA-
A2) (WoÈlfel et al, 1994), tyrosinase 368±376 (HLA-A2, with a post-
translational conversion of asparagine to aspartic acid at position 370)
(Skipper et al, 1996a), tyrosinase 206±214 (HLA-A24) (Kang et al, 1995),
tyrosinase 192±200 (HLA-B44) (Brichard et al, 1996), tyrosinase 243±251
and its two modi®ed counterparts C244A and C244S (HLA-A1)
(Kittlesen et al, 1998), gp100 17±25 (HLA-A3) (Skipper et al, 1996b),
gp100 87±95 (HLA-A3) (Kawashima et al, 1998), gp100 209±217
T210M (HLA-A2) (Parkhurst et al, 1996), gp100 280±288 A288V
(HLA-A2) (Parkhurst et al, 1996), Melan-A/MART-1 26±35 A27L
(HLA-A2) (Valmori et al, 1998), Melan-A/MART-1 32±40 (HLA-A2)
(Castelli et al, 1995). The amino acid sequences of these peptides have
been reported in the above-cited references. The control peptide was
derived from HIV NEF protein: NEF 186±194, DSRLAFHHV (HLA-
B51). The degree of purity of each peptide was above 90%. The
lyophilized peptides were diluted to 1 mg per ml in distilled water
containing 10% dimethylsulfoxide, and then aliquoted and stored at ±
20°C.
Tumor cell lines Melanoma cell line BOU (HLA-A2/-A66, -B50/-
B41) was obtained by enzymatic digestion of a subcutaneous metastasis.
DEL (HLA-A1/-A3, -B35/-B39) and CHO (HLA-A1/-A11, -B42/-
B44) were provided by Dr. P. Paul. IGR1/54 was provided by Dr. F.
Jotereau (HLA-A2/-A3, -B58/-). These cell lines were grown in RPMI
1640 medium with Glutamax supplemented with 10% fetal bovine
serum, nonessential amino acids, HEPES, and antibiotics. BOU, IGR1/
54, CHO, and DEL expressed Melan-A/MART-1, gp100, and
tyrosinase, con®rmed by reverse transcription polymerase chain reaction
(RT-PCR) and immunostaining.
Histology Biopsy samples were taken from the inner periphery (active
margin) of vitiligo patches from ®ve melanoma patients. They were ®xed
in alcohol±formalin±acetic acid and then embedded in paraf®n. Sections
5 mm thick were stained with hematoxylin±eosin±saffron for standard
histologic analysis. Immunohistochemical staining was performed on
nonadjacent sections after microwave pretreatment, using the following
primary antibodies: polyclonal anti-CD3 (Dako-A0452, Glostrup,
Denmark), monoclonal anti-CD4 (Novocastra-1F6, Newcastle, U.K.),
monoclonal anti-CD8 (Novocastra-AB11), and monoclonal anti-CD56
(Zymed Laboratory-123C3, San Francisco, CA). Anti-CD3 was revealed
with the Envision polyclonal system (Dako). The Envision monoclonal
system (Dako) was used to reveal anti-CD8 and anti-CD56. Finally,
anti-CD4 was revealed using the CSA system (Dako).
Expansion of VIL Biopsy specimens were minced and placed in
culture medium (RPMI supplemented with 10% human serum) in six-
well plates. IL-2 (100 IU per ml, Boehringer, Mannheim, Germany) was
added to the cell cultures once a week. VIL were ®rst harvested within
1±3 wk of culture. The same method was used for the expansion of
lymphocytes in®ltrating cutaneous lesions of lichen planus and secondary
syphilis.
Short-peptide stimulation of PBMC PBMC were isolated by density
gradient centrifugation through a lymphocyte separation medium (Ficoll-
Hypaque, Pharmacia, Uppsala, Sweden).
In order to expand peptide-speci®c CD8+ T cells, fresh unfractionated
PBMC were seeded in 24-well plates (4 3 106 per well) in RPMI
medium with Glutamax (Gibco Laboratories, Grand Island, NY), supple-
mented with 10% human serum, nonessential amino acids, HEPES, and
antibiotics. To each well were added the various peptides (three to six
peptides per well) at a ®nal concentration of 1 mg per ml. IL-2 (10 IU
per ml) was added on days 3 and 7. Stimulated PBMC were tested in an
IFN-g Elispot assay on day 12.
IFN-g Elispot assay The IFN-g Elispot assay was adapted from that of
el Ghazali et al (1993). Brie¯y, 96-well nitrocellulose plates (Millipore,
Bedford, MA) were coated with 1 mg per ml of mouse antihuman IFN-g
capture monoclonal antibody (MoAb) (1-D1K, Mabtech, Nacka,
Sweden) diluted with phosphate-buffered saline (PBS) and incubated
overnight at 4°C. The wells were washed with PBS-Tween 0.05% and
saturated with complete RPMI medium. VIL or stimulated PBMC (4 3
104±105 per well) were plated in duplicate or triplicate with various
CD8+ epitopic peptides (1 mg per ml) or with target cells (5 3 103 per
well) and incubated for 20 h at 37°C under 5% CO2. The wells were
then washed and incubated for 1 h with 100 ml of biotinylated mouse
antihuman IFN-g (1 mg per ml; 7-B-6 Mabtech, Nacka, Sweden).
Alkaline-phosphatase-labeled Extravidin (Sigma, St. Louis, MO) was then
added for 1 h. Finally, 100 ml of a chromogenic alkaline phosphatase
conjugate substrate (Bio-Rad, Hercules, CA) was added to each well to
reveal the spots. Finally, spots were counted using a computer-assisted
video image analysis (Zeiss, Jena, Germany).
Flow cytometry For the ®rst ¯ow cytometry analysis (Fig 2A later),
anti-CD3-FITC, anti-CD4-PE, anti-CD8-FITC, anti-CD16 + CD56-
PE, and anti-CLA HECA-452 (Becton-Dickinson, Le Pont de Claix,
France) were used according to the manufacturer's instructions.
Fluorescein isothiocyanate rabbit antirat Ig antibody (Dako) was used as
second-step reagent for indirect immuno¯uorescence staining with
HECA-452. Fluorescence-activated cell sorter (FACS) analysis was
performed using a FACScan apparatus (Becton-Dickinson).
For the second ¯ow cytometry analysis (Fig 2B later) the cells were
initially surface stained for 30 min at room temperature with anti-CD8-
APC (clone SK1, IgG1), anti-CD56-PE (clone NCAM16.2, IgG2b), and
anti-CD45-FITC (clone HI100, IgG2b) (Becton-Dickinson). The cells
were then washed and resuspended in 1% paraformaldehyde. Samples
were evaluated using a FACScalibur ¯ow cytometer (Becton-Dickinson)
and data were analyzed with Lysis software (Becton-Dickinson). For each
sample 104 events were acquired, gated on CD8 expression with a scatter
gate designed to include only viable lymphocytes.
T cell receptor b-variable region (TCR-BV) repertoire analysis
Total RNA was obtained from thawed ex vivo PBMC, in vitro cultured
PBMC, and VIL, using the method of Chomczynsky and Sacchi (1987)
(RNAble kit; Eurobio, Paris, France). Pellet Paint was used as a
coprecipitant during isopropanol precipitation. RNA was resuspended in
30 ml of RNAse-free water and stored at ±80°C until use. TCR-BV
repertoire analysis was performed as previously described (Prevost-
Blondel et al, 1995). Brie¯y, total RNA was reverse transcribed with
random hexamers to which were added oligo(dT) 16 primers and
murine leukemia virus reverse transcriptase (Perkin Elmer, Foster City,
CA) according to the manufacturer's instructions. cDNAs were PCR-
ampli®ed using the 24 Vb-speci®c probes and a common Cb-speci®c
probe labeled with Fam ¯uorescent dye (Genset, Paris, France). All
primers used in this study have been described elsewhere (Martinon et al,
1999). Each Vb±Cb PCR product was analyzed by electrophoresis in
agarose gel. For the analysis of CDR3 length diversity, PCR products
were electrophoresed in an ABI 373 A DNA sequencer (Perkin Elmer).
Data were analyzed for fragment size and ¯uorescence intensity with
Immunoscope 3.01d software.
RESULTS
Histologic analysis Skin biopsy samples were taken from the
active margin (inner border) of vitiligo patches of ®ve melanoma
patients. All the specimens had the histopathologic features of
vitiligo, such as loss of melanocytes in the basal cell layer of the
epidermis (revealed by Fontana staining) and presence of an
in¯ammatory in®ltrate in the super®cial dermis and in the basal
layer of the epidermis, composed of small, well-differentiated
lymphocytes often located in perivascular and periannexial areas
(Fig 1). Immunohistochemical analysis of the biopsy specimen
from all ®ve patients showed that the in®ltrating lymphocytes,
particularly in the basal layer of the epidermis, were almost
exclusively CD3+, and predominantly CD8+ (Fig 1). Very few
cells were stained with anti-CD56 (not shown).
Expanded cells are T cells expressing the cutaneous
lymphocyte antigen (CLA) Cutaneous lymphocytes gradually
proliferated and remained in close contact with the skin fragments
when minced vitiligo biopsy specimens were placed in culture. No
lymphocyte expansion was observed with a normal skin specimen
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from patient 1 (not shown). Suf®cient cells were recovered from
vitiligo samples from patient 3 only, in order to determine their
phenotype by FACS analysis (Fig 2). Following 3 wk of culture,
87% of expanded cells expressed CD3 antigen, showing that they
were predominantly T lymphocytes. These VIL were
predominantly CD8+. Only 11% of expanded VIL from this
patient expressed CD56 and/or CD16 antigens (markers of natural
killer cells). Immunohistochemical analysis of the biopsy specimens
from the ®ve patients also showed very slight staining by anti-
CD56 and anti-CD16 monoclonal antibodies (not shown). To
further determine the phenotype of VIL, we performed a triple
staining of CD8/CD56 and CD45RA expression and a cytometric
analysis (Fig 2B). Sixty-four percent of CD8+ VIL were
CD45RA±/CD56±, indicating a memory phenotype, and 32%
were CD8+/CD45RA+/CD56±, suggesting a naive phenotype
(although some memory cells may revert to CD45RAhigh: Bell et al,
1998). Only 4% of the CD8+ VIL were CD56+ and 1% expressed
both CD56 and CD45RA. Half of the CD56+ VIL were CD8±,
i.e., natural killer cells (not shown). Altogether, these results suggest
that very few in vitro expanded VIL have a CD8+/CD56+ cytolytic
phenotype.
Almost all (97%) expanded VIL expressed CLA, ruling out
expansion of contaminating blood T cells. Indeed, merely 26% of
freshly isolated autologous PBMC were found to express CLA (not
shown). When expanded VIL were separated from the skin
fragments and seeded in microwells, CLA expression fell to 34%
after 3 d (not shown). This observation is in agreement with the
results from Fuhlbrigge et al (1997) who used freshly isolated and
cultured PBMC.
The TCR repertoire of VIL is biased In order to investigate
whether VIL were antigenically stimulated, we studied their TCR
repertoire. In patient 3, Vb usage was studied in VIL using RT-
PCR (see Materials and Methods). As control, the same experiment
was performed using ex vivo (thawed) PBMC and in vitro expanded
PBMC cultured in the same conditions as VIL (3 wk with 100 UI
per ml IL-2). In vitro expanded PBMC, as well as nonexpanded
PBMC, showed an ampli®cation of all Vb±Cb families [except for
Vb11, which is associated with natural killer cells (Dellabona et al,
1994)]. In contrast, not all Vb families were expressed by VIL,
further con®rming that expanded cells were not derived from
contaminating circulating T cells (Fig 3). Moreover, immunoscope
analysis of the VIL TCR repertoire showed a clonal or oligoclonal
pro®le of CDR3 length distribution (refer to Fig 3; one
Figure 2. Expanded VIL are T cells expressing the CLA. A biopsy
sample was taken from the active margin of a vitiligo patch in patient 3.
The specimen was minced and placed in culture medium containing
IL-2. VIL were harvested after 3 wk of culture and tested for their
expression of CD3, CD4, CD8, CD16+CD56, and CLA (A) and CD8,
CD56, and CD45RA (B) by ¯ow cytometry. The distribution of CD56
and CD45RA expression is shown among the viable (R1) CD8+ (R2)
T cells.
Figure 1. Immunohistochemical staining for CD4+ and CD8+ T
lymphocytes in an alcohol±formalin±acetic acid ®xed paraf®n-
embedded vitiligo biopsy specimen from patient 1. (A) A small
proportion of CD4+ T cells in the lymphocytic in®ltrate are solely
located in the super®cial dermis. Original magni®cation 2003. (B) The
lymphocytic in®ltrate is predominantly CD8+. Interestingly, lymphocytes
are exclusively CD8+ in the basal layer of the epidermis, where
melanocytes are usually located (in a normally pigmented skin). Scale bar:
5 mm.
1466 LE GAL ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
representative experiment out of three experiments with the same
pattern of responses). In contrast, CDR3 size distribution in
autologous ex vivo PBMC was Gaussian. In cultured PBMC,
oligoclonal or clonal distributions of CDR3 size were also observed
in some Vb families, probably due to a certain in vitro selection.
Nevertheless, although not proving it, the biased TCR repertoire
of VIL could suggest their antigenic stimulation.
VIL recognize melanocyte differentiation antigens The
antigen speci®city of VIL was assessed by an IFN-g Elispot assay
following 1±3 wk of culture. Unfractionated VIL were tested against
peptides derived from the melanocyte-lineage-speci®c antigens
Melan-A/MART-1, gp100, and tyrosinase, depending on the
patients' HLA phenotype (Fig 4A). An HIV-derived peptide was
used as negative control. For each assay, a cut-off value of speci®c
secretion of IFN-g was determined, based on the number of
nonspeci®c spots obtained after stimulation with the control peptide
(cut-off = mean background + 3 SEM). Because PBMC from
patients with melanoma can contain melanoma differentiation
antigen speci®c CTL precursors, VIL and peptide-activated PBMC
(see Materials and Methods) were compared for their reactivity against
the same set of peptides (Fig 4A, B). CD8+ VIL recognized peptides
derived from pigment cell lineage speci®c proteins involved in
melanin synthesis, such as tyrosinase, Melan-A/MART-1, or gp100.
As controls, several samples of skin lesions from other skin conditions
were placed in a culture medium. Lymphocytes extracted from
lesions of lichen planus and of cutaneous secondary syphilis did not
recognize any of the peptides derived from melanocyte antigens (Fig
4C). In addition, PBMC and VIL from patient 4 had a similar
recognition pattern. In patients 1 and 3, certain peptides were
recognized by both VIL and PBMC (MART 26±35 27L in patient
1, Tyr192±200 in patient 3); others were recognized by either
PBMC or VIL. In PBMC from patients 2 and 5, a high background
noise was observed and no speci®c response to the tested
melanocyte-derived peptides could be detected.
To further characterize the CD8+ VIL of patients 1, 3, and 4, we
tested their ability to recognize naturally processed antigens on
melanoma cells. An IFN-g Elispot assay was performed with several
melanoma cell lines as targets, sharing only one HLA-A class I locus
with the patients' VIL, or having no matches (control). VIL from
patients 1, 3, and 4 recognized one or several peptides naturally
presented by melanoma cells in association with HLA-A2 (patients
1 and 4) or HLA-A3 (patient 3) (Fig 5). Weak IFN-g secretion in
response to K562 stimulation, attributable to natural killer activity,
was consistent with the very small proportion of CD16+ CD56+
cells identi®ed by immunohistology and FACS analysis.
DISCUSSION
The increased frequency of vitiligo in patients with autoimmune
hormonal disorders has long suggested that autoimmunity could be
responsible for melanocyte destruction in this setting. Early studies
focused on the identi®cation of a humoral response against
melanocytic antigens. Since the early 1980s, several authors have
reported the detection of antibodies against melanocyte-speci®c
antigens (Naughton et al, 1983; Cui et al, 1992), tyrosinase in
particular (Song et al, 1994), in the serum of patients with vitiligo.
The better prognosis of melanoma patients who develop vitiligo
(Nordlund et al, 1983; Bystryn et al, 1987; Duhra and Ilchyshyn,
1991) is also indicative of an autoimmune mechanism, in which the
immune response against malignant melanocytes would also destroy
normal ``bystander'' melanocytes by targeting antigens shared by
the two cell types. Antibodies directed against shared melanocyte
antigens have indeed been found in patients with isolated or
melanoma-associated vitiligo (Cui and Bystryn, 1995; Baharav et al,
1996; Merimski et al, 1996).
Little work has been done on the possible role of T cells in
vitiligo. Recently, Ogg et al showed that cytolytic CD8+ T cells
directed against the melanocytic differentiation antigen derived
epitope MART 26±35 were more frequent in peripheral blood of
nonmelanoma vitiligo patients than in healthy subjects (Ogg et al,
1998). Becker et al identi®ed clonally expanded T cells with
identical BV regions in melanoma and surrounding vitiligo, i.e., in
areas of destruction of both normal and neoplastic cells. This
observation strongly suggested a role of T-cell-mediated anti-
tumoral response in the development of melanoma-associated
vitiligo (Becker et al, 1999). More recently, Yee et al identi®ed
Melan-A/MART-1-speci®c CD8+ T cells in in¯ammatory lesions
following infusion of Melan-A/MART-1-speci®c CD8+ T cell
clones in melanoma patients (Yee et al, 2000).
In this study, we addressed the role of CD8+ T cells in
melanoma-associated vitiligo using functional tests. For this pur-
pose, we preferred to focus on the local immune response rather
than to limit our analysis to the systemic response. Histologic
analysis of vitiligo biopsy specimens always showed a lymphocytic
in®ltrate. This was also previously observed at the active margins of
vitiligo lesions (Nordlund and Lerner, 1982; Badri et al, 1993). In
keeping with the results of previous studies, we observed a strong
predominance of CD3+ lymphocytes and an increased CD8/CD4
ratio, especially in the basal layer of the epidermis where
melanocyte destruction takes place. These results outline a role of
CD8+ T cells in vitiligo (Badri et al, 1993; Le Poole et al, 1996).
Following a 3 wk culture, the in vitro expanded VIL were almost
exclusively CD8+ T cells. At this time, their CD56/CD45RA
expression did not reveal a cytolytic pro®le, according to the recent
work of Pittet et al (Pittet et al, 2000; 2001), but rather
corresponded to memory (64%) and probably naive (32%) popu-
lations. We cannot rule out, however, that the CD45RAhigh VIL
are memory cells (i.e., CD45RAlow cells) that have switched back
to a CD45RAhigh phenotype (Bell et al, 1998). Moreover, these
®ndings concern in vitro cultured cells and may not re¯ect the in vivo
Figure 3. Analysis of the TCR repertoire of
VIL and PBMC from patient 3. Total RNA
recovered from thawed PBMC, and from PBMC
and VIL after 3 wk of culture, was extracted and
reverse transcribed. cDNAs were PCR-ampli®ed
using the 24 Vb-speci®c probes and a common
¯uorescent Cb-speci®c probe. Each Vb±Cb PCR
product was analyzed by electrophoresis in agarose
gel. X signi®es that the Vb±Cb PCR product is
detectable using this method; O means that no
product could be detected. CDR3 length diversity
was evaluated by electrophoresis of PCR products
using a DNA sequencer and data were analyzed
with Immunoscope software (open squares, no
PCR product identi®ed by agarose gel
electrophoresis; hatched squares, Gaussian, i.e.
polyclonal, distribution of CDR3 sizes; gray
squares, oligoclonal distribution; black squares:
clonal distribution).
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situation. Nevertheless, the scarce presence of CD56+ cells revealed
by the immunohistochemistry analysis of the initial biopsies
suggests that destruction of melanocytes could occur through a
noncytolytic pathway. As long as they were allowed to remain in
close contact with the skin fragments in the tissue-culture plates,
in vitro expanded VIL expressed the CLA homing molecule. This is
in keeping with immunohistologic results of Badri et al (1993).
Expanded T cells were not derived from contaminating blood, as
con®rmed by the high proportion of VIL expressing CLA and the
altered TCR-BV repertoire of expanded VIL. Furthermore, the
restricted Vb usage and the clonal or oligoclonal pro®le of the
CDR3 length distribution in expanded VIL from patient 3 may
suggest their activation or recruitment at the lesion site.
Nevertheless, as demonstrated by Dietrich et al (1997), a repertoire
selection may occur during in vitro lymphocyte culture. This was
con®rmed by the CDR3 size analysis of in vitro expanded PBMC
compared to that of noncultured PBMC of patient 3, showing that
our culture conditions were, to some extent, responsible for an
in vitro selection. It was therefore essential to analyze the antigenic
reactivity of VIL by means of indisputable functional tests. IFN-g
Figure 4. Speci®c recognition of melanocyte-antigen-derived
peptides by VIL and PBMC determined in an IFN-g Elispot
assay. VIL from patients 1, 2, 3, 4, and 5 were harvested between 2 and
4 wk of culture (A). PBMC from the same patients were cultured for
12 d with IL-2 and melanocyte-antigen-derived peptides able to associate
with the patients' HLA molecules (B). As control, cells from other skin
conditions (lichen planus and secondary syphilis) were extracted and
cultured in the same conditions as VIL and tested in an IFN-g Elispot
assay for their reactivity toward melanoma antigens. The horizontal line
crossing the histograms represents the cut-off value de®ning speci®c
IFN-g secretion (mean background + 3 SEM). Cells were incubated in
nitrocellulose plates coated with an antihuman IFN-g monoclonal
antibody (5 3 104 cells per well), together with the test peptides (1 mg
per ml) for 20 h. The number of IFN-g-secreting cells was determined
by revealing the spots formed on the nitrocellulose membrane after
incubation of the plates with a biotinylated antihuman IFN-g
monoclonal antibody followed by alkaline-phosphatase-labeled Extravidin
and then alkaline phosphatase conjugate substrate. Each spot corresponds
to one IFN-g-secreting cell. Results are the means of triplicates 6 SEM.
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Elispot assays showed that VIL speci®cally secreted IFN-g in
response to several melanocyte-derived antigenic epitopes that
were expressed on both normal melanocytes and melanoma cells.
Moreover, these VIL recognized antigenic peptides naturally
processed by melanoma cells (Fig 5). In contrast, T cells expanded
from lichen planus and secondary syphilis lesions in the same
culture conditions as VIL did not recognize any melanocyte-
derived antigens. In two patients (2 and 5), no melanocyte-speci®c
response could be demonstrated in the peripheral blood. Therefore,
the response of these patients would have escaped detection by
merely analyzing the systemic immune response. Altogether,
PBMC and VIL did not present the same pattern of reactivity in
four out of ®ve patients (Fig 4A, B). This underlines the necessity
of analyzing immune responses at the site in which they are likely
to occur. To our knowledge, this work is the ®rst to show the
direct and functional evidence that CD8+ T cells, directed against
several melanocytic antigens, can play a role in vitiligo naturally
occurring in melanoma patients. Ogg et al showed the increased
frequency of MART 26±35 speci®c cytolytic CD8+ T cells in
peripheral blood of patients having vitiligo in the absence of
melanoma (Ogg et al, 1998). We further observed a speci®c
reactivity toward several other melanocyte-derived antigenic
epitopes (®ve peptides derived from gp100, four peptides derived
from Melan-A/MART-1) in the peripheral blood of a 65-y-old
patient with ``spontaneous'' widespread vitiligo (data not shown).
These observations suggest that the tumor is not necessary to prime
the melanoma-speci®c T cells and that, in nonmelanoma patients,
this autoimmune cellular reactivity has its origins in another
phenomenon. Nevertheless, several lines of evidence suggest that
vitiligo is probably linked with an antitumoral response in
melanoma patients. For example, we have observed a higher
frequency of melanoma-associated antigen-speci®c CD8+ reactivity
in the peripheral blood of melanoma patients with vitiligo than in
melanoma patients without vitiligo (manuscript in preparation).
This observation is in accordance with the frequent occurrence of
vitiligo in melanoma patients receiving immunotherapy (Le Gal et
al, 1996; Rosenberg and White, 1996; Buendia-Eisman et al, 1997)
and also with its possible link with better prognosis (Nordlund et al,
1983; Bystryn et al, 1987). These observations, together with the
results of this study, suggest that vitiligo in melanoma patients could
be the visible consequence of a cellular antitumoral response,
although not predictive of the clinical outcome of this immune
reaction.
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